Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

81. Prediction models for childhood asthma onset: a systematic review

Prediction models for childhood asthma onset: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

82. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis

Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

83. Phenotypes of atopic dermatitis for predicting the risk of asthma: a systematic review and meta-analysis

Phenotypes of atopic dermatitis for predicting the risk of asthma: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

84. Traditional Chinese medicine on treating asthma: a systematic review

Traditional Chinese medicine on treating asthma: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

85. Vitamin D supplementation in pregnant or breastfeeding women or young children for preventing asthma [Cochrane protocol]

Vitamin D supplementation in pregnant or breastfeeding women or young children for preventing asthma [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

86. Sputum colour as a marker for the presence of bacteria in acute exacerbations of asthma and COPD

Sputum colour as a marker for the presence of bacteria in acute exacerbations of asthma and COPD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

87. Short-term exposure to O3, NO2 and SO2 and emergency department visits and hospital admissions due to asthma

Short-term exposure to O3, NO2 and SO2 and emergency department visits and hospital admissions due to asthma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

88. Psychological interventions for asthma in children and adolescents [Cochrane protocol]

Psychological interventions for asthma in children and adolescents [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

89. How effective is an escalation in ICS preventer therapy and is there an optimal increase to prevent asthma exacerbations for children and young people within supported self-management?

How effective is an escalation in ICS preventer therapy and is there an optimal increase to prevent asthma exacerbations for children and young people within supported self-management? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

90. As needed combined long acting beta agonists and inhaled corticosteroids in mild asthma: meta-analysis and systematic review

As needed combined long acting beta agonists and inhaled corticosteroids in mild asthma: meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

91. As-needed therapy in asthma: a network meta-analysis

As-needed therapy in asthma: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

92. Community-based paediatric asthma management pathways - a systematic review

Community-based paediatric asthma management pathways - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

93. Diagnostic accuracy of periostin in asthma: a systematic review and meta-analysis of prospective studies

Diagnostic accuracy of periostin in asthma: a systematic review and meta-analysis of prospective studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

94. Bronchial thermoplasty for severe asthma

Bronchial thermoplasty for severe asthma Bronchial thermoplasty for se Bronchial thermoplasty for sev vere asthma ere asthma Interventional procedures guidance Published: 19 December 2018 nice.org.uk/guidance/ipg635 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However (...) should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. This guidance replaces IPG419. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of bronchial thermoplasty for severe asthma is adequate to support

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

95. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. (PubMed)

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Epidemiological evidence has suggested a link between use of beta₂-agonists and increased asthma mortality. Much debate has surrounded possible causal links for this association, and whether regular (daily) long-acting beta₂-agonists (LABAs) are safe, particularly when used in combination with inhaled corticosteroids (ICSs). This is an update of a Cochrane Review that now includes data from two large trials (...) including 11,679 adults and 6208 children; both were mandated by the US Food and Drug Administration (FDA).  OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS.We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trials registers for unpublished trial data. We also checked FDA

2018 Cochrane

96. Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma

Tiotropium (Spiriva Respimat) add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma Tiotropium (Spiriva ® Respimat ® ). Reference number 1882. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Tiotropium (Spiriva ® Respimat ® ) 2.5 microgram, inhalation solution Company: Boehringer Ingelheim Ltd Licensed indication under consideration: add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe (...) asthma who experienced one or more severe asthma exacerbations in the preceding year Date of licence extension: 12 April 2018 Comparator(s) The company stated that there is no comparator and that tiotropium (Spiriva ® Respimat ® ) is an add-on treatment. Limited submission details ? The limited submission criteria were met based on a minor licence extension. Clinical effectiveness ? Tiotropium (Spiriva ® Respimat ® ) was recommended by the All Wales Medicines Strategy Group in 2017 as an add

2018 All Wales Medicines Strategy Group

97. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its (...) treatment we present studies showing a dose-response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes and osteoporosis as well as psychiatric disorders, was higher for patients with long-term exposure to OCS compared with control groups. In addition

2018 EvidenceUpdates

98. Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST

Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata (...) .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} An asthma self-management plan that advised patients to temporarily quadruple their dose of inhaled corticosteroid reduced asthma exacerbations, with fewer serious adverse events and at lower cost. {{author}} {{($index , , , , , , , , , , , , , , , & . Tricia McKeever 1 , Kevin Mortimer 2 , Lucy Bradshaw 3 , Rebecca Haydock 3 , Ian Pavord 4 , Bernard Higgins 5 , Samantha Walker 6 , Andrew Wilson 7 , David Price 8, 9 , Mike

2018 NIHR HTA programme

99. Limited clinical value of exhaled volatile organic compound measurements in childhood asthma (Full text)

Limited clinical value of exhaled volatile organic compound measurements in childhood asthma Exhaled volatile organic compound measurements do not aid the clinician diagnosing asthma in children http://ow.ly/Z2d930lpZ60.

2018 ERJ open research PubMed

100. Asthma severity and fertility outcome in women with polycystic ovary syndrome: a registry-based study (Full text)

Asthma severity and fertility outcome in women with polycystic ovary syndrome: a registry-based study Recent research suggests that women with polycystic ovary syndrome (PCOS) have a higher risk of asthma. However, the severity of asthma, use of antiasthma medication and effect on fertility have yet to be investigated. In a case-control cross-sectional registry study using the Danish National Patient Register and other Danish registries, asthma prevalence, asthma severity, antiasthma medication (...) use and fertility outcome were investigated among two groups of women with PCOS (n=1358 and n=17 123) and a healthy control group (n=5340). Both asthma prevalence (OR 1.45, 95% CI 1.24-1.70) and mean daily inhaled corticosteroid dose were higher among women with PCOS compared with healthy controls, whereas asthma severity was the same in women with and without PCOS. Women with PCOS and asthma had more in vitro fertilisation treatments than women in the control group with asthma, but the numbers

2018 ERJ open research PubMed